Unlike recent deals for psoriasis drugs, Prurisol

Unlike recent deals for psoriasis drugs, Prurisol may qualify for three or five years of market exclusivity if approved. If its annual sales is 50% of Otezla ($500M), that's an additional $1.5B (3 years) or $2.5B (5 years) of revenue. I'm sure Leo will point that out to the potential partner, in addition to the smaller cost for Phase 3.

Quote:

---

I'm sure the partner they are going announce will want to get it through quickly also and cost will be less of an issue to them!

---